Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07867873 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surgery Versus Stereotactic Ablative Radiotherapy for Patients With Locally Advanced Pancreatic Cancer With Favourable Biological Response Following Induction Chemotherapy

Study acronym: PREOPANC-4 RCT
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to assess the added value of surgical exploration with intention for resection compared to MRI guided stereotactic ablative radiotherapy (SABR) in improving overall survival in patients with locally advanced pancreatic carcinoma (LAPC) who show a favourable biological response to systemic induction chemotherapy.
Trial Details
NCT Number NCT07867873
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Erasmus Medical Center, University Hospital Verona, Italy, University Hospital Heidelberg, Catharina Ziekenhuis Eindhoven, St. Antonius Hospital, Leiden University Medical Center, Radboud University Medical Center, University Medical Center Groningen, Maastricht University Medical Center, San Raffaele University Hospital, Italy, West China Hospital, Institut Paoli-Calmettes, University Hospital, Essen, Copenhagen University Hospital, Denmark, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, University Hospital Padova, University Hospital Ulm, Assistance Publique - Hôpitaux de Paris, Ruijin Hospital, Tubingen University Hospital
Conditions Locally Advanced Pancreatic Carcinoma (LAPC)
Enrollment 230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov